Epigenetic mechanisms of liver tumor resistance to immunotherapy - Sorbonne Université
Article Dans Une Revue World journal of hepatology Année : 2021

Epigenetic mechanisms of liver tumor resistance to immunotherapy

Résumé

Hepatocellular carcinoma (HCC) is the most common primary liver tumor, which stands fourth in rank of cancer-related deaths worldwide. The incidence of HCC is constantly increasing in correlation with the epidemic in diabetes and obesity, arguing for an urgent need for new treatments for this lethal cancer refractory to conventional treatments. HCC is the paradigm of inflammation-associated cancer, since more than 80% of HCC emerge consecutively to cirrhosis associated with a vast remodeling of liver microenvironment. In the recent decade, immunomodulatory drugs have been developed and have given impressive results in melanoma and later in several other cancers. In the present review, we will discuss the recent advancements concerning the use of immunotherapies in HCC, in particular those targeting immune checkpoints, used alone or in combination with other anti-cancers agents. We will address why these drugs demonstrate unsatisfactory results in a high proportion of liver cancers and the mechanisms of resistance developed by HCC to evade immune response with a focus on the epigenetic-related mechanisms.
Fichier principal
Vignette du fichier
WJH-13-979.pdf (6.8 Mo) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-03376117 , version 1 (13-10-2021)

Identifiants

Citer

Julie Sanceau, Angélique Gougelet. Epigenetic mechanisms of liver tumor resistance to immunotherapy. World journal of hepatology, 2021, 13 (9), pp.979-1002. ⟨10.4254/wjh.v13.i9.979⟩. ⟨hal-03376117⟩
105 Consultations
90 Téléchargements

Altmetric

Partager

More